Browsing Tag
ESMO Congress 2024
3 posts
Bristol Myers Squibb’s Opdivo and Yervoy combination shows unprecedented 10-year survival benefits in advanced melanoma
Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term…
Scorpion Therapeutics unveils promising Phase 1/2 clinical data for STX-478 in advanced solid tumors
Scorpion Therapeutics, Inc. has presented initial clinical data from its Phase 1/2 trial of STX-478, a mutant-selective PI3Kα…
Breakthrough liver cancer treatment: Merck’s new drug combo slashes disease progression risk by 34%
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have…